Paclitaxel disrupts polarized entry of membrane‑permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death

Best,Charles; Calianese,David; Szulak,Kevin; Cammarata,Garret; Brum,Gabriella; Carbone,Thomas; Still,Eric; Higgins,Katelyn; Ji,Fang; Di,Wen; Wanebo,Harold; Wan,Yinsheng

doi:10.3892/ol.2013.1305

Paclitaxel disrupts polarized entry of membrane‑permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death

Authors:
- Charles Best
- David Calianese
- Kevin Szulak
- Garret Cammarata
- Gabriella Brum
- Thomas Carbone
- Eric Still
- Katelyn Higgins
- Fang Ji
- Wen Di
- Harold Wanebo
- Yinsheng Wan
View Affiliations

Affiliations: Department of Biology, Providence College, Providence, RI 02918, USA, Department of Obstetrics and Gynecology, Renji Hospital of Shanghai Jiaotong University Medical School, Shanghai 200001, P.R. China, Department of Surgery, Landmark Medical Center, Woonsocket, RI 02895, USA
Published online on: April 16, 2013 https://doi.org/10.3892/ol.2013.1305
Pages: 1854-1858

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Exogenous cell‑permeable C6 ceramide has been demonstrated to act synergistically with chemotherapeutic drugs, including paclitaxel, cisplatin, doxorubicin and the histone deacetylase inhibitor, trichostatin A, to induce cell death in a variety of cancer cells. We previously demonstrated that C6 ceramide and paclitaxel function synergistically to induce ovarian cancer cell death via modulation of the PI3/AKT cell survival pathway. In the present study, the entry pattern of C6 ceramide into ovarian cancer cells was investigated using fluorescent short chain C6‑NBD sphingomyelin (C6‑NBD). Confocal microscopy revealed that C6‑NBD enters the cells in a polarized pattern, characterized by marked signals at one cellular end, representing a likely mitosis initiation site. Pretreatment of the cells with filipin, an inhibitor of the lipid raft/caveolae endocytosis pathway, decreases C6‑NBD entry into the cells. A pretreatment with the water channel inhibitor, CuSO4, was also found to reduce the entry of C6‑NBD. Notably, the pretreatment with paclitaxel was shown to disrupt the polarized entry of C6‑NBD into the cells, resulting in an even distribution of C6‑NBD in the cytoplasm. In addition, the pretreatment of the cells with paclitaxel destabilized the cytoskeletal proteins, releasing an increased number of short tubulin fragments. The results of the present study indicate that C6 ceramide preferentially enters the cells via a predetermined initiation site of mitosis. In addition to diffusion, short chain C6 ceramide may also enter cells via water channels and caveolae‑mediated endocytosis. Paclitaxel disrupts the cell cytoskeleton and induces an even distribution of C6 ceramide in the cytoplasm resulting in synergistic ovarian cancer cell death.

View Figures

View References

1	Bourteele S, Hausser A, Döppler H, Horn-Müller J, Röpke C, Schwarzmann G, Pfizenmaier K and Müller G: Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid synthases by caspases in apoptotic Kym-1 cells. J Biol Chem. 273:31245–31251. 1998. View Article : Google Scholar
2	Zhan D, Santin AD, Liu Y, Parham GP, Li C, Meyers C and Hermonat PL: Binding of the human papillomavirus type 16 p97 promoter by the adeno-associated virus Rep78 major regulatory protein correlates with inhibition. J Biol Chem. 274:31619–31624. 1999. View Article : Google Scholar : PubMed/NCBI
3	Chapman JV, Gouazé-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, Barth BM, Liu X, Liu YY, Giuliano AE and Cabot MC: Metabolism of short-chain ceramide by human cancer cells - implications for therapeutic approaches. Biochem Pharmacol. 80:308–315. 2010. View Article : Google Scholar : PubMed/NCBI
4	Lavie Y, Cao HT, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE and Cabot MC: Agents that reverse multidrug resistance, tamoxifen, verapamil and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem. 272:1682–1687. 1997. View Article : Google Scholar
5	Chang MS, Sasaki H, Campbell MS, Kraeft SK, Sutherland R, Yang CY, Liu Y, Auclair D, Hao L, Sonoda H, Ferland LH and Chen LB: HRad17 colocalizes with NHP2L1 in the nucleolus and redistributes after UV irradiation. J Biol Chem. 274:36544–36549. 1999. View Article : Google Scholar : PubMed/NCBI
6	Lucci A, Giuliano AE, Han TY, Dinur T, Liu YY, Senchenkov A and Cabot MC: Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int J Oncol. 15:535–540. 1999.PubMed/NCBI
7	Giussani P, Bassi R, Anelli V, Brioschi L, De Zen F, Riccitelli E, Caroli M, Campanella R, Gaini SM, Viani P and Riboni L: Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. Cancer Invest. 30:27–37. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lucci A, Han TY, Liu YY, Giuliano AE and Cabot MC: Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol. 15:541–546. 1999.PubMed/NCBI
9	Carlier MF and Pantaloni D: Taxol effect on tubulin polymerization and associated guanosine 5′-triphosphate hydrolysis. Biochemistry. 22:4814–4822. 1983.
10	Myrick D, Blackinton D, Klostergaard J, Kouttab N, Maizel A, Wanebo H and Mehta S: Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leuk Res. 23:569–578. 1999. View Article : Google Scholar : PubMed/NCBI
11	Gatei M, Young D, Cerosaletti KM, Desai-Mehta A, Spring K, Kozlov S, Lavin MF, Gatti RA, Concannon P and Khanna K: ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat Genet. 25:115–119. 2000. View Article : Google Scholar : PubMed/NCBI
12	Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE and Cabot MC: Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol. 47:444–450. 2001. View Article : Google Scholar : PubMed/NCBI
13	Liu Y, Qiu L and Li C: Effect of radiation on nasal mucosa and the microvascular casting of guinea pig. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 20:793–796. 2006.(In Chinese).
14	Devalapally H, Duan Z, Seiden MV and Amiji MM: Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer. 121:1830–1838. 2007. View Article : Google Scholar : PubMed/NCBI
15	Kolesnick R, Altieri D and Fuks Z: A CERTain role for ceramide in taxane-induced cell death. Cancer Cell. 11:473–475. 2007. View Article : Google Scholar : PubMed/NCBI
16	Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, Brenton JD, Downward J and Nicke B: Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell. 11:498–512. 2007. View Article : Google Scholar : PubMed/NCBI
17	Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, Jones NP, East P, Nicke B, Spassieva S, Obeid LM, Birkbak NJ, Szallasi Z, McKnight NC, Rowan AJ, Speirs V, Hanby AM, Downward J, Tooze SA and Swanton C: CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol. 226:482–494. 2012. View Article : Google Scholar
18	Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Wanebo H, Kouttab N, Chu W and Wan Y: Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. Oncol Rep. 16:907–913. 2006.PubMed/NCBI
19	Kuebler WM, Yang Y, Samapati R and Uhlig S: Vascular barrier regulation by PAF, ceramide, caveolae and NO - an intricate signaling network with discrepant effects in the pulmonary and systemic vasculature. Cell Physiol Biochem. 26:29–40. 2010. View Article : Google Scholar
20	Hara-Chikuma M, Chikuma S, Sugiyama Y, Kabashima K, Verkman AS, Inoue S and Miyachi Y: Chemokine-dependent T cell migration requires aquaporin-3-mediated hydrogen peroxide uptake. J Exp Med. 209:1743–1752. 2012. View Article : Google Scholar : PubMed/NCBI
21	Virreira M, Perret J and Delporte C: Pancreatic beta-cells: Role of glycerol and aquaglyceroporin 7. Int J Biochem Cell Biol. 43:10–13. 2011. View Article : Google Scholar : PubMed/NCBI
22	Zheng X and Bollinger Bollag W: Aquaporin 3 colocates with phospholipase d2 in caveolin-rich membrane microdomains and is downregulated upon keratinocyte differentiation. J Invest Dermatol. 121:1487–1495. 2003. View Article : Google Scholar : PubMed/NCBI
23	Cao C, Sun Y, Healey S, Bi Z, Hu G, Wan S, Kouttab N, Chu W and Wan Y: EGFR-mediated expression of aquaporin-3 is involved in human skin fibroblast migration. Biochem J. 400:225–234. 2006. View Article : Google Scholar : PubMed/NCBI
24	Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di W and Wan Y: Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol. 62:857–865. 2008. View Article : Google Scholar : PubMed/NCBI
25	Kelland LR: Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 10:413–424. 2005. View Article : Google Scholar : PubMed/NCBI